To help people with hypoparathyroidism in the U.S. who are facing out-of-pocket medical costs, The Assistance Fund (TAF)…
Articles by Patricia Inácio, PhD
Dosing is underway in a Phase 2 clinical trial of MBX 2109, an investigational hormone replacement therapy for people with…
Treatment with Ascendis Pharma’s TransCon PTH (palopegteriparatide) for up to two years leads to sustained improvements in the kidney…
People with higher body fat — as measured by body mass index, or BMI — have a lower risk of…
A natural history study of hypoparathyroidism taking place at Columbia University Irving Medical Center in New York has started to…
Amolyt Pharma has raised €130 million (roughly $138 million) to support the clinical development of eneboparatide, previously AZP-3601,…
Central lymph node dissection, or the removal of lymph nodes in the neck, increases the risk of both temporary and…
The U.S. Food and Drug Administration (FDA) has greenlit an expanded access program (EAP) for Ascendis Pharma to allow…
Ascendis Pharma is seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism in the European Union, the…
Less experienced surgeons and removing lymph nodes in the neck during thyroid surgery are the main risk factors of accidentally…